Kathleen Scott Sells Shares of Dermata Therapeutics, Inc. $DRMA

Written by Podchat · Published · Updated

Key Points

  • Kathleen Scott sold 11 shares of Dermata Therapeutics, Inc. ($DRMA) worth $13.09.
  • $DRMA last traded around $1.19.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Kathleen Scott, insider at Dermata Therapeutics, Inc. ($DRMA), sold 11 shares at an average price of $1.19, for a total transaction of $13.09. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Dermata Therapeutics, Inc. Stock Down 11.2%

Shares of Dermata Therapeutics, Inc. ($DRMA) traded around $1.19 on Wednesday, down 11.2% for the day.

Last price$1.19
Market cap$6.39M
Forward P/E-0.33
Beta0.66
52-week low$0.95
52-week high$6.22
50-day MA$1.31
200-day MA$1.63
Current ratio2.81
Quick ratio2.41

Dermata Therapeutics, Inc. Earnings

EPS (ttm)-$4.06
Revenue (ttm)—
Net margin0%
Return on equity-183.89%
Next earningsMay 14, 2025

Analysts Set New Price Targets

Average target$4
High target$4
Low target$4
Analysts covering1

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

ExchangeNasdaqCM
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
CEOMr. Gerald T. Proehl
Employees9
Websitehttps://www.dermatarx.com

Get Dermata Therapeutics, Inc. alerts

New 13F filings, insider trades, and analyst moves on $DRMA, sent to your inbox. Free, and you can unsubscribe anytime.

Related Filing Alerts

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.